CLINICAL CANDIDATES

The Company’s lead clinical candidates, SRX251 and SRX246, are first-in-class, CNS-penetrating, high affinity, high selectivity V1a receptor antagonists that are orally bioavailable. These compounds represent a potential breakthrough approach for the treatment of major depression and treatment-resistant depression, anxiety disorders including post-traumatic stress disorder, intermittent explosive disorder, and impulsive aggression/violent behavior.

SRX246 and SRX251 are being developed as novel therapeutics for stress-related CNS disorders, including depression, PTSD, and Intermittent Explosive Disorder. Pre-clinical studies with these compounds were supported by the National Institutes of Health through multiple SBIR grants, the National Toxicology Evaluation Program, and the RAID Program, and SBIR grants. In the U.S. alone, these disorders affect more than 40 million people and pharmaceutical treatments represent an estimated $25 billion annual market.

Successful Phase I Clinical Trials with SRX251 and SRX246 have established safety and tolerability with repeat dosing.

Both SRX251 and SRX246 reduce measures of depression, anxiety, stress, aggression, and fear in preclinical models. In addition, neuroimaging and behavioral investigations show that the compounds selectvely block stress, arousal, and fear in social interaction models without impacting other behaviors. Azevan believes that this unique combination of properties demonstrates exceptional promise for vasopressin antagonists as a novel approach to treating disorders of stress, mood, and behavior.